🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Heat Shock Protein 47 in Thrombosis

Recruitingn/aAges 18 Years - anyAllUniversity of Aarhus
NCT06731673 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to learn if the novel biomarker Heat shock protein 47 (HSP47) can be used as a prognostic marker for vascular disease in people with acute venous thromboembolism (VTE), myocardial infarction (AMI) or ischaemic stroke compared to healthy volunteers. The main questions it aims to answer are: 1. Are platelet levels of HSP47 higher in patients with acute VTE, AMI or stroke, compared to healthy volunteers. 2. Does platelet levels of HSP47 remain elevated in patients with acute thrombotic events compared to healthy volunteers at 3 and 12-months of follow-up. 3. Are platelet levels of HSP47 postively associated with platelet function and negatively associated with fibrinolytic capacity in patients with an acute thrombotic event. Participants with VTE, AMI or stroke will be giving a blood sample at diagnosis and again after 3 and 12 months of follow-up.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * 18 years of age or older * Informed consent VTE group: * Deep vein thrombosis confirmed on ultrasonography OR * Pulmonary embolism confirmed on computed tomography angiography (CTA) AMI group: * ST-segment elevation on electrocardiogram (ECG) AND * Culprit lesion(s) on coronary angiography Stroke group: * Stroke confirmed on magnetic resonance imaging AND * Atrial fibrillation (Detected on ECG, telemtry or Holter monitoring) AND * Stroke localisation classic for AFib: cortical, cerebellar, brainstem or subcortical \>1.5 cm in diameter Healthy group: \- Healthy Exclusion Criteria: * \<18 years of age * no informed consent * Known haematological disorders * Active haematological malignancy * Severe renal insufficiency defined as eGFR \<15 or dialysis VTE - Pulmonary embolism incidentally detected by CTA conducted for purposes unrelated to pulmonary embolism assessment without concomitant DVT AMI * Coronary dissection * Takotsubo cardiomyopathy Stroke \- Stroke from other causes, e.g. findings pointing towards large vessel disease Healthy * Known acute or chronic disease * Prior VTE, AMI, stroke or other thromboembolic event
💊

What it tests

  • Not listed
📍

Where

2 sites
Aarhus University Hospital
Aarhus, Denmark
Deutsches Herzzentrum de Charité
Berlin, Germany
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy